Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX

Comparison shows improved survival rates for pancreatic cancer treatment

Alligator Bioscience has announced positive outcomes from indirect treatment comparison studies, showing that mitazalimab combined with mFOLFIRINOX significantly improves overall survival (OS) for metastatic pancreatic adenocarcinoma cancer (mPDAC) patients.

The OPTIMIZE-1 trial, which lacked a control group, used published literature from Phase 2/3 studies for this comparison.

The data revealed that mitazalimab + mFOLFIRINOX has better OS compared to FOLFIRINOX-based and NALIRIFOX regimens. Hazard ratios were 0.64 (95% CI 0.46 – 0.87) and 0.68 (95% CI 0.47 – 0.99) respectively. These findings will inform the upcoming Phase 3 trial.

“These results underscore the positive clinical data delivered by mitazalimab, reaffirming its potential to transform metastatic pancreatic cancer treatment,” said Søren Bregenholt, CEO of Alligator Bioscience. “We eagerly anticipate the 24-month follow-up data, expected later this quarter.”

Dr Zev Wainberg of UCLA added: “ITC is an acknowledged methodology in health outcomes research. The improvement in survival indicated by these results substantiates mitazalimab combined with chemotherapy as a frontline therapy, to be evaluated in the upcoming Phase 3 study.”

The results were presented on January 24 at the 2025 ASCO Gastrointestinal Cancers Symposium.

These findings provide further momentum as Alligator continues to refine standards of care and improve outcomes for patients with this devastating disease.

The encouraging survival benefits demonstrated through this analysis contribute to the growing body of evidence supporting mitazalimab’s potential in treating metastatic pancreatic cancer.